COVITREM-1 - Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19
Head :
GIBOT Sébastien
Last update : 05/06/2021 | Version : 1 | ID : 73586
| General | |
| Identification | |
| Detailed name | Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19 |
| Sign or acronym | COVITREM-1 |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | NCT04544891 |
| General Aspects | |
| Medical area |
Anesthesiology – Intensive care Infectious diseases |
| Study in connection with Covid-19 |
Yes |
| Pathology (details) | patients hospitalised due to Covid-19 |
| Keywords | biomarker, COVID-19 |
| Scientific investigator(s) (Contact) | |
| Name of the director | GIBOT |
| Surname | Sébastien |
| s.gibot@chru-nancy.fr | |
| Organization | Nancy Regional University Hospital |
| Collaborations | |
| Participation in projects, networks and consortia |
Yes |
| Funding | |
| Funding status |
Public |
| Details | BPI France |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Nancy Regional University Hospital |
| Organisation status |
Public |
| Presence of scientific or steering committees |
Yes |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Cohort study |
| Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
| Database recruitment is is made on the basis of: |
Another treatment or procedure |
| Database recruitment is carried out as part of an interventional study |
No |
| Database objective | |
| Main objective | Evaluate the prognostic value of initial TREM-1 activation (first measurement collected) on clinical deterioration in patients hospitalised due to COVID-19 in medical, emergency and intensive care departments |
| Inclusion criteria |
Patients aged over 18 years
Hospitalised for less than 3 days for any reason whatsoever, but screened for Covid-19. SARS-CoV-2 infection should be "probable" or "confirmed" according to the definition published on 3 April by Santé Publique France (French Public Health Agency): laboratory confirmation (by positive RT-PCR further to nasopharyngeal sample or any other sample and/or positive serology indicating infection) or by a composite endpoint combining characteristic pulmonary impairment upon imaging and clinical/laboratory effects suggesting viral infection (including: fever, cough, chest pain, and biological inflammatory syndrome, lymphopenia, elevated liver enzymes). Registered with a social security scheme or a beneficiary of such a scheme The patient or their representative will have received information on the study and signed the emergency informed consent/inclusion form in compliance with Article L.1122-1-3 of the French Public Health Code (CSP) |
| Population type | |
| Age |
Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population covered |
Sick population |
| Pathology | J96 - Respiratory failure, not elsewhere classified |
| Gender |
Male Woman |
| Geography area |
National |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 2020 |
| Size of the database | |
| Size of the database (number of individuals) |
[1000-10 000[ individuals |
| Details of the number of individuals | 1009 |
| Data | |
| Database activity |
Current data collection |
| Type of data collected |
Clinical data Biological data |
| Clinical data (detail) |
Direct physical measures |
| Presence of a biobank |
Yes |
| Contents of biobank |
Serum Plasma DNAc/RNAm |
| Health parameters studied |
Health event/morbidity Health event/mortality |
| Procedures | |
| Participant monitoring |
Yes |
| Monitoring procedures |
Monitoring by contact with the participant (mail, e-mail, telephone etc.) |
| Links to administrative sources |
No |
| Promotion and access | |
| Promotion | |
| Access |
